JP2017523789A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523789A5
JP2017523789A5 JP2017506395A JP2017506395A JP2017523789A5 JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5 JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
subject
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523789A (ja
JP6723982B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043792 external-priority patent/WO2016022671A1/en
Publication of JP2017523789A publication Critical patent/JP2017523789A/ja
Publication of JP2017523789A5 publication Critical patent/JP2017523789A5/ja
Application granted granted Critical
Publication of JP6723982B2 publication Critical patent/JP6723982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506395A 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法 Active JP6723982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
US62/033,726 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020108721A Division JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Publications (3)

Publication Number Publication Date
JP2017523789A JP2017523789A (ja) 2017-08-24
JP2017523789A5 true JP2017523789A5 (enExample) 2018-09-13
JP6723982B2 JP6723982B2 (ja) 2020-07-15

Family

ID=53836871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017506395A Active JP6723982B2 (ja) 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Country Status (32)

Country Link
US (3) US12084483B2 (enExample)
EP (2) EP3177307B1 (enExample)
JP (3) JP6723982B2 (enExample)
KR (1) KR102653758B1 (enExample)
CN (2) CN107074967B (enExample)
AU (3) AU2015301071C1 (enExample)
BR (1) BR112017001940A2 (enExample)
CA (1) CA2957273C (enExample)
CL (1) CL2017000284A1 (enExample)
CO (1) CO2017002166A2 (enExample)
DK (1) DK3177307T3 (enExample)
EA (2) EA202091342A3 (enExample)
ES (1) ES2986097T3 (enExample)
FI (1) FI3177307T3 (enExample)
HR (1) HRP20241258T1 (enExample)
HU (1) HUE068478T2 (enExample)
IL (2) IL250007B (enExample)
LT (1) LT3177307T (enExample)
MA (2) MA40094B1 (enExample)
MX (1) MX388977B (enExample)
MY (1) MY180831A (enExample)
PE (1) PE20170503A1 (enExample)
PH (1) PH12017500042A1 (enExample)
PT (1) PT3177307T (enExample)
RS (1) RS65930B1 (enExample)
SA (1) SA517380842B1 (enExample)
SG (2) SG10201913695PA (enExample)
SI (1) SI3177307T1 (enExample)
SM (1) SMT202400414T1 (enExample)
TN (1) TN2017000020A1 (enExample)
WO (1) WO2016022671A1 (enExample)
ZA (1) ZA201700245B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN111423513A (zh) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11780899B2 (en) 2017-12-06 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to IL-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12280119B2 (en) 2018-03-23 2025-04-22 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
BR112020018709A2 (pt) * 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
CA3133414A1 (en) * 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向MAdCAM之免疫耐受性
KR20220012256A (ko) * 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
CN119591725A (zh) * 2019-07-12 2025-03-11 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
WO2021055568A1 (en) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
CA3157229A1 (en) * 2019-10-18 2021-04-22 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之il2促效劑及其使用方法(二)
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023524077A (ja) 2020-04-30 2023-06-08 イテオ バイオセラピー,インク. 活性可能なil2の組成物および使用方法
WO2022036079A1 (en) * 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
KR20240149421A (ko) * 2022-02-11 2024-10-14 뮤럴 온콜로지, 인코포레이티드 암 면역요법을 위한 조성물 및 방법
US20250154216A1 (en) * 2022-02-16 2025-05-15 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
TW202434646A (zh) * 2023-02-22 2024-09-01 大陸商百奧賽圖(北京)醫藥科技股份有限公司 抗il2ra抗體及其用途
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US20040265272A1 (en) 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
WO2005091956A2 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
LT3401402T (lt) 2012-06-08 2020-12-28 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2017523789A5 (enExample)
FI3177307T3 (fi) Interleukiini-2/interleukiini-2-reseptori alfa-fuusioproteiinit ja niiden käyttömenetelmät
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
CA3086842A1 (en) Il-2 variant
RU2017101436A (ru) Mic-1 слитные белки и их применение
JP2014525901A5 (enExample)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
RU2014135053A (ru) Иммуногены для вакцинации против вич
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
JP2015524413A5 (enExample)
JP2014510519A5 (enExample)
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
JP2015511599A5 (enExample)
CN121319219A (zh) Il2突变蛋白
NZ760008A (en) Uti fusion proteins
RU2010141916A (ru) Растворимый мутант рецептора фактора некроза опухоли
JP2016019527A (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
KR20240164594A (ko) 설계된 사이토카인 조성물 및 사용 방법
AU2018200638A1 (en) Immunotherapeutic composition, therapeutic method and diagnostic method
AU2024288570A1 (en) Designed interleukin-2 cytokine compositions and methods for use
JP6431476B2 (ja) オステオプロテゲリン由来の組成物およびその使用
WO2023071390A1 (zh) 一种重组白介素-15变体
CN116375880A (zh) 融合蛋白及其制备方法和应用
Wei et al. Cloning and characterization of goose interleukin-17A cDNA
US20100055135A1 (en) Enhancin of hepatitis b virus vaccine and its gene